Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice
Article first published online: 22 DEC 2003
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 110, Issue 3, pages 311–314, March 2003
How to Cite
Italian Association of Haemophilia Centres (AICE): Register of acquired factor VIII inhibitors (RIIA) (2003), Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG: An International Journal of Obstetrics & Gynaecology, 110: 311–314. doi: 10.1046/j.1471-0528.2003.01535.x
- Issue published online: 22 DEC 2003
- Article first published online: 22 DEC 2003
- Accepted 11 December 2002
Objective To review the clinical problems related to the inhibitor of factor VIII (FVIII) in pregnancy.
Design Retrospective analysis.
Setting Haemophilia and haemotology centres.
Population Patients registered and followed up at the centres.
Methods Data were collected from the Italian Haemophilia Register of acquired FVIII inhibitor.
Results Twenty of 96 cases with FVIII inhibitor were identified postpartum. The time of appearance was 3–150 days postpartum. All but one of the cases were idiopathic; 11/20 patients required blood transfusions. In six patients, the inhibitor was identified because of surgical bleeding, four after hysterectomies carried out because of postpartum haemorrhage. A prolonged activated partial thromboplastin time was present in all women in whom the test was carried out. Nine women did not require treatment because the bleeding was mild; in 11 patients bleeding was promptly controlled by different therapeutic modalities. Immunosuppressive therapy was used to suppress the inhibitor. The majority of the patients who achieved complete remission received steroids; in 6/6 patients who relapsed, a second remission was obtained with combined therapy.
Conclusions In a review of 20 pregnancies with FVIII inhibitor, over a 15 year period, bleeding was controlled in all cases with no fatalities. Correct evaluation of coagulation screening tests, in particular, activated partial thromboplastin time, is essential.